Heart and Blood Diseases

All Conditions

Rare Diseases

Thromboembolism

Venous Thromboembolism

Thrombosis

Embolism

Embolism and Thrombosis

Vascular Diseases

Acute Graft Versus Host Disease

Micronutrients

All Drugs and Chemicals

Antineoplastic Agents

Pharmaceutical Solutions

Anticoagulants

Coagulants

Fibrinolytic Agents

Central Nervous System Depressants

Vitamins

Other Dietary Supplements

Vitamin A

Retinol palmitate

Warfarin

Vitamin K

Heparin, Low-Molecular-Weight

Tinzaparin

Dalteparin

Benzocaine

Retinol

Menadione

Menaquinone

Naphthoquinone

Phylloquinone

Tannic Acid

Oral treatment with warfarin in combination with overlapping initial (5 to 10 days) treatment with Innohep®.

Tablets. Once daily for 6 months (180 days) to maintain therapeutic international normalised ratio (INR) levels in combination with initial (5-10 days) overlapping treatment with Innohep®.

Solution for sub-cutaneous injection, pre-filled syringes. Once daily for 6 months (180 days). 175 anti Xa IU/kg.

Innohep®

Agnes Y. Y. Lee, MD, MSc, FRCPC

The purpose of this study is to assess the efficacy and safety of Innohep® in preventing the recurrence of VTE in patients with active cancer who have had an acute VTE episode.

Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer

Efficacy and Safety of Long-Term (6 Months) Innohep® Treatment Versus Anticoagulation With a Vitamin K Antagonist (Warfarin) for the Treatment of Acute Venous Thromboembolism in Cancer Patients / IN 0901 INT

* Symptomatic non-fatal DVTs.
* Symptomatic non-fatal PEs.
* Fatal PE.
* Incidental proximal DVT (popliteal vein or higher).
* Incidental proximal PE (segmental arteries or larger).

* The 5 individual components of the composite primary efficacy endpoint.
* A composite endpoint of symptomatic DVT and/or PE, including fatal PE.

Safety endpoints will consist of bleeding and overall mortality

LEO Pharma

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer	NCT01130025	Venous Thromboe...	Warfarin Innohep®	18 Years -	LEO Pharma
Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer	NCT01130025	Venous Thromboe...	Warfarin Innohep®	18 Years -	LEO Pharma

Spots Global Cancer Trial Database for innohep®

Every month we try and update this database with for innohep® cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for innohep®

Every month we try and update this database with for innohep® cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for innohep® cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.